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Modiﬁer geneCaenorhabditis elegans comprises unique features that make it an attractive model organism in diverse ﬁelds of
biology. Genetic screens are powerful to identify genes and C. elegans can be customized to forward or reverse
genetic screens and to establish gene function. These genetic screens can be applied to “humanized” models of
C. elegans for neurodegenerative diseases, enabling for example the identiﬁcation of genes involved in protein
aggregation, one of the hallmarks of these diseases. In this review, wewill describe the genetic screens employed
in C. elegans and how these can be used to understand molecular processes involved in neurodegenerative and
other human diseases. This article is part of a Special Issue entitled: From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
1.1. Caenorhabditis elegans as a model organism
Sydney Brenner ﬁrst introduced the nematode C. elegans as a genetic
model organism in 1965 and since then themodel has been extensively
used in very diverse ﬁelds of research, from developmental biology to
ecotoxicology, aging and neuroscience [1]. This has resulted in several
breakthroughs in biomedical science, which include the discovery of
genetic regulators of programmed cell death, the use of the green ﬂuo-
rescent protein as a protein marker, and the discovery of RNA interfer-
ence. Indeed, this nematode combines a number of characteristics that
make it an advantageous model, anatomically and genetically, which
are summarized in Box 1. Moreover, the characteristics of this inverte-
brate make it an easy experimental model to study biological processes
in a relatively cheap, quick, and easy way.
C. elegans is a small, free-living nematode of about 1–1.5 mm in
length that can be found in temperate soil environments feeding on
different bacteria, including Escherichia coli. It exists in two sexual
forms, as a hermaphrodite or as a male. The former is self-fertile, able
to produce its own sperm and eggs and is the predominant adultnome to Function.
ights reserved.form. Althoughmales are rare (about 0.02%), their abundance in the off-
spring can be increased to 50% bymating with hermaphrodites [2]. The
length of the life cycle of wild type N2 C. elegans strains and its lifespan
depends on the growth temperature. Grown at 20 °C, hermaphrodites
usually lay 300–350 eggs and once the eggs hatch, it takes about three
days to develop from a larva to an adult. The average lifespan of this or-
ganism can vary between 18 and 20 days [3,4]. At higher temperatures,
the life cycle is shortened and the lifespan decreased. Onemajor advan-
tage of C. elegans is that it has awell-dissected and predetermined anat-
omy. The adult hermaphrodite has exactly 959 somatic cells and 302
neurons [1,5,6]. Its transparent body enables one to easily follow cell
fate or expression of ﬂuorescently tagged proteins of interest in the
living animal. Moreover, C. eleganswas the ﬁrst multicellular organism
to have the complete genome sequenced and this gave rise to several
databases and resources that are currently available online for the sci-
entiﬁc community ([7], see “Online links” at the end of this article).
Genetic screens are widely used in C. elegans to discover gene func-
tion. It can be easily applied to discover which gene mutations are re-
sponsible for a speciﬁc phenotype of interest (forward genetics) or,
conversely, the gene function can be purposely altered to assess what
is the consequence in terms of development, behavior or alterations in
speciﬁc biological processes (reverse genetics). The two major genetic
screens employed are ethyl methane sulfate (EMS) screens and (ge-
nome-wide) RNAi screens. They have been fundamental not only to
dissect nematode genetics but also to identify genes involved in aging,
development, DNA damage response, and signal transduction, amongst
other biological processes [8–13].
Box 1
Advantages of using Caenorhabditis elegans as a model organism
1. Small size (1–1.5mm long)
2. Short reproductive cycle
3. Short lifespan
4. Translucent body
5. Precise, predetermined anatomy
6. Ease of culture
7. Small genome
8. Whole genome sequenced
9. RNAi library available
10. Deletion mutant database
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For the scope of this review, we shall explore the rationale and the
basic procedures for bothmethods not only highlighting their advantages
but also pinpointing the drawbacks. Next, we will explore how genetic
screens can help us gain insight into the molecular and cellular mecha-
nisms of human diseases. Speciﬁcally, we will focus on the application
of genetic screens to discover potential disease-modiﬁer genes by exem-
plifying studies on C. elegansmodels for neurodegenerative diseases.
There are a signiﬁcant number of proteins that are evolutionary
conserved between C. elegans and humans. At the time that the C.
elegans genome sequencing was complete, 36% of C. elegans proteins
(from a set composed of 18,891 protein sequences) were found to
have homologs in humans (set composed of 4979 protein sequences),
by pairwise comparison (The C. elegans Sequencing Consortium, 1998
[7]). Thereafter, this percentage was increased to 83% due to the much
larger human gene dataset available to perform the comparison [14]. A
more recent study estimated that 38% of the 20,250 C. elegans protein-
coding genes had unique corresponding functional orthologs in humans
(7663 unique hits) [15]. In a nutshell, biological processes unraveled in
the invertebrate C. elegans can provide insight into human biology.2. Genetic screens
Genetic screens in C. elegans are well-established and commonly
used to assess gene function in any biological process of interest.
High-throughput (semi-) automatized setups and screening methods
enable hundreds of parallel experiments inmicrotiter plates. In a screen,
wild type animals are mutagenized or treated with RNAi and then
scored for phenotypical changes. Belowwe describe two types of genet-
ic screens that are most frequently used: EMS mutagenesis and RNATable 1
Features of EMS mutagenesis versus RNA interference.
EMS mutagenesis RNA interference
Inactivation or alteration of gene function Reduction or depletion of gene function
Requires identiﬁcation of gene mutation Candidate gene is known
Permanent mutation Possible to select developmental stage
for depletion
No effects on embryos in the ﬁrst
generation
Can select for non-essential genes Can identify roles of essential genes in
a post-developmental process
Limited penetrance to neurons
Limited efﬁciency if the protein that is
encoded by the targeted gene is very
stableinterference (RNAi). The characteristics of both type of screens are sum-
marized in Table 1.
2.1. EMS mutagenesis
Themost commonly usedmethod tomutate the genome of C. elegans
is the treatment with EMS. The mutagen induces mutations in the
sperm and oocytes of hermaphrodites. Sydney Brenner tested system-
atically different mutagens, but researchers are mostly using EMS
because of its relatively low toxicity and relatively good efﬁciency
(summarized in [16]). The hermaphroditism of C. elegans allows easy
maintenance of a mutation as a homozygous worm will pass it to all
the progeny through self-fertilization.
Mutations can be identiﬁed using a simple F2 screenﬁrstly described
by Brenner in 1974 [1]. Thousands of copies of any particular gene can
be analyzed in a typical EMS screen. The frequency of a null mutation
at any particular locus of the genome is one for every 2000 copies by
using standard concentrations (50 mM) of the mutagen. That means
that one can expect to identify 6 mutations per particular gene in a typ-
ical experiment of 12,000 haploid genomes (reviewed in [16]). The
mutagenized worms are placed on Petri dishes and grown for two gen-
erations to produce homozygous mutants (Fig. 1). Worms from the F2
generation showing a speciﬁc phenotype of interest are further singled
to newplates to determinewhether the phenotype is transmitted to the
next generation.
Once a worm with a speciﬁc phenotype is isolated, the responsi-
ble mutation needs to be identiﬁed. By using single nucleotide poly-
morphisms (SNPs) of the Hawaiian wild type strain in comparison
to the Bristol strain (natural variation wild type) it is possible toFig. 1.High-throughputmutagenesis screen in C. elegans: Animals (P0) are treated with a
mutagen (e.g. EMS) to produce progeny (F1) containing mutations in alleles of different
genes. These animals get progeny (F2) of different genotypes by self-fertilization which
are further scored for a speciﬁc phenotype. Positive evaluated animals are singled to
validate a homozygous mutation by breeding through of the phenotype to the next
generation (F3). Once a mutant is isolated, the mutation site needs to be mapped to a
speciﬁc genomic site to continue with functional studies (adapted from [16]).
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steps to a speciﬁc region on that chromosome. When a mutation is
mapped to a gene region, sequencing or the speciﬁc knockdown of
every single gene in that area by RNAi can be used to identify themutat-
ed gene. The development of new sequencing methods like deep se-
quencing in the last decade facilitates the identiﬁcation of mutations
and can save laborious ﬁne mapping [18–20]. It is important to keep
in mind that an isolated, mutated animal can have several mutations
at different loci. For further interpretation, it is therefore necessary to
backcross the animals several times with wild type strains. The impor-
tance for controlling the genetic background was shown by Burnett
and colleagues. They demonstrated that a described lifespan extension
[21] by overexpression of SIR-2 disappeared after several backcrossings
[22]. Tissenbaum and Guarente further showed that the overexpression
of SIR-2.1 slightly increases lifespan but to amuch lesser extent than the
transgenic animals used in their ﬁrst publication [23]. Deep sequencing
methods can be used to monitor mutations in the background. Prefer-
entially, one should use independent mutant or deletion alleles of a
gene to conﬁrm results.
In the ﬁrst EMS screens, 619 mutants were identiﬁed with visible
phenotypes especially from the uncoordinated class [1]. This group of
genes impairs wild type movements when mutated. Under laboratory
conditions proper moving is not essential as food is plentiful and sex
is dispensable so therefore maintenance and characterization of mu-
tants that may not survive in non-laboratory conditions are possible.
Many of these mutants have revealed important information about
molecules and mechanisms involved in human disease. For example,
one gene of the uncoordinated class is unc-2 (uncoordinated 2) and en-
codes for a homolog of the voltage-sensitive calcium-channel alpha-1
subunit (human P/Q calcium channel CACNA1A) [24]. Missense muta-
tions in the CACNA1A calcium channel in humans are associated with
a rare form of migraine [25] which is often associated with low levels
of serotonin [26]. unc-2mutants show neuronal migration defects sim-
ilar to serotonin-deﬁcient mutants [27] and UNC-2 is required for the
desensitization to the two neurotransmitters dopamine and serotonin
[28]. Studies using C. elegans showed that UNC-2 interacts with the
transforming growth factor (TGF)-β, a pathway that is required for
movements through regulation of serotonin levels probably through
the modulation of the expression of tph-1 (tryptophan hydroxylase),
the enzyme that converts tryptophan into serotonin [29]. There are
elevated levels of TGF-β1 in migraine patients compared to those of
pain-free individuals [30].
In addition to mutations in the uncoordinated class, Brenner also
identiﬁed mutants with aberrant appearance like animals with small
bodies, blistered cuticles, twitching muscles, rolling locomotion, long
bodies, dumpy bodies, forked heads or bent heads [1].
EMS screens are often used to identify different mutations with the
same phenotype to further investigate if those genes function in the
sameprocesses. Using this approach, John Sulston andH. Robert Horvitz
searched e.g. for mutants that show defects in the differentiation of a
vulva from epidermal cells [31]. Molecular follow-up studies revealed
that animals that lack a vulva hadmutations in two signaling pathways:
the epidermal growth factor (EGF)/RAS pathway and the Notch signal-
ing pathway (reviewed in [32–34]), both having major roles in cell fate
determination. These studies in C. elegans have increased the under-
standing of these molecular pathways involved in oncogenesis in
humans (reviewed in [35,36]).
Another possibility to ﬁnd genes of the same genetic pathways are
enhancer or suppressor screens. In this case the mutagenesis occurs
on a non-wild type strain whose genetic composition is known and
causes a deﬁned phenotype. Like this, one can screen for mutations in
this genetic background that enhance or suppress (reverse) that pheno-
type.With this approach one is able to show that two genes not only act
in the same pathway but also their hierarchy which means that one is
acting upstream of the other (summarized in [16]). However, one
should still keep in mind that it might also be possible that someproteins result in the same phenotype when mutated even though
they do not necessarily function in the same pathway.
Although EMS mutagenesis is a powerful tool to generate a high
number of mutations and high-throughput screens to identify mutants
with a speciﬁc phenotype it also has some limitations. It has been
estimated that about 30% of the genes in C. elegans can be mutated to
a visible phenotype [37] (some mutations might result e.g. in a lethal
phenotype as it is the case for a number of developmental genes) and
it needs to be mentioned that the identiﬁcation of the same mutations
which indicates a saturation of the screen is no guarantee that some
other genes might be missed in this screen. High-throughput screens
are only a starting point for further detailed experiments at molecular
levels.
2.2. RNA interference
RNA interference was ﬁrst discovered and investigated in C. elegans
and published in 1998 by Andrew Fire et al. [38] (Nobel Prize in Physi-
ology and Medicine in 2006). The discovery of dsRNA-mediated gene
silencing has revolutionized genetic studies in C. elegans, as well as in
other model organisms. Similar to EMS screens, RNAi screens can be
used to identify genes that, when depleted, result in a certain phenotype
or enhance or suppress a mutant phenotype.
RNAi in C. elegans is systemic, which, to date, is not the case for any
other animal models. Therefore it is sufﬁcient to introduce dsRNA into
one speciﬁc tissue to get RNA silencing also in distant cells because of
an ampliﬁcation process called transitive RNAi [39]. This systemic effect
is advantageous for large-scale genome-wide RNAi screens in C. elegans.
There are different methods that describe how to silence gene ex-
pression in C. elegans. The dsRNA can be delivered into the worm by
(1) injection into any region [38], (2) feeding with dsRNA-producing
bacteria [40], (3) soaking in dsRNA [41] or (4) in vivo production of
dsRNA from transgenes under the control of speciﬁc promotors [42].
Cell-speciﬁc factors seem to regulate thereby the entry and export of
dsRNA [39,43,44]. Some cell types (e.g. neurons) seem not to respond
well to systemically delivered RNAi [42]. The use of RNAi enhancedmu-
tants (e.g. eri-1mutant or mutants of the retinoblastoma pathway that
are described to enhance RNAi especially in nervous tissue) might cir-
cumvent this problem [45,46]. In addition, Calixto and colleagues gener-
ated transgenic animals overexpressing the transmembrane protein
SID-1 which is an essential component for systemic RNAi in the neu-
rons. This modiﬁcation increased the response to dsRNA delivered by
feeding. It seemed that the expression of SID-1 in the neurons, on the
other hand, decreased the RNAi effect on non-neuronal cells which
might be useful for studying the function of essential genes in the neu-
rons. This effect could be even increased when using a sid-1 mutant
background [47]. Durieux and colleagues further used this mutant that
is insensitive for systemic RNAi to investigate the knockdown of one
of the cytochrome c oxidase-1 subunits in speciﬁc tissues by controlling
the expression of dsRNA via tissue-speciﬁc promotors [48]. The tissue-
speciﬁc expression of SID-1 (not only in neurons) in a sid-1 knockout
background probably also enables to study tissue-speciﬁc effects espe-
cially of essential genes.
Especially the possibility to feed animalswith dsRNA-producingbac-
teria enables to perform high-throughput RNAi screens in C. elegans
(Fig. 2) [49,50]. For efﬁcient induction of RNA interference the choice
of the dsRNA-coding region is essential. In C. elegans, long dsRNA frag-
ments (more than 100 bp) trigger gene silencing via RNAi. For most
genes dsRNA is about 200–1000 nucleotides or even longer and covers
exon-regions of the targeted gene. The fragment should only target
one gene. Once the coding region is chosen it can be cloned into a spe-
ciﬁc vector encoding the production of the speciﬁc dsRNA (summarized
in [51]). The L4440 vector contains two bacteriophage T7 RNA polymer-
ase promotors ﬂanking the multiple cloning site in which the cDNA of
a speciﬁc gene has been inserted. The construct can be transformed
into E. coli strain HT115 (ED3). This strain is deﬁcient for the bacterial
Fig. 2.High-throughputRNAi screen inC. elegans: Age-synchronized animals are transferred tomicrotiter plates containing different clones of HT115 E. colibacteria. Every cloneproduces a
speciﬁc dsRNA which is taken up by the nematodes and induces a knockdown of the corresponding gene. Positive hits in the phenotypic screen are ﬁnally conﬁrmed by sequencing the
bacterial clone and repeating the speciﬁc knockdown in single experiments. Starting point of the RNAi feeding (possible at any developmental stage) and time point of the phenotypic
scoring depend on the experiment setup.
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from the construct can be induced by the addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG). The bacteria are then synthesizing two
complementary RNA strands that form a duplex RNA which can medi-
ate RNAi [38].
RNAi libraries are commercially available which includes one library
of bacteria clones containing cDNAs of 17,575 genes which represents
about 87% of the C. elegans genome [49] and one library including clones
of 11,800 C. elegans genes [52]. Positive scored clones subsequently can
be sequenced to conﬁrm that they target the predicted gene. To prevent
any further off-target effects of the dsRNA and therefore false-positive
results, one should consider generating a second RNAi construct
targeting the mRNA of the same gene [52]. Besides the coding regions,
the 3′UTR ofmRNAmight aswell be a suitable target as RNA localization
elements for the transport of the mRNA or regulation elements of eu-
karyotic gene expression are typically located in this region (summa-
rized in [53,54]).
Dissolving adult hemaphrodites with hypochloride (bleach) will
yield only fertilized eggs and can be used to age-synchronize the ani-
mals for a screen.
Gene knockdown by RNAi can be induced at different developmen-
tal stages in contrast to EMSmutagenesis, which generates stablemuta-
tions that are present at all stages. Thus, the examination of the function
of a gene that is transcribed at different developmental stages is possi-
ble. This is especially interesting when an active gene is essential at
early developmental stages [55]. To investigate the effect of gene deple-
tion by RNAi during embryonic development it is necessary to feed the
parental worm with the speciﬁc bacterial strain.
Another possibility to study the effect of gene depletion at a certain
timepoint was previously described by Calixto and colleagues, by
performing a temperature-sensitive conditional knockdown. They
could induce the knockdown of a gene by controlling via temperature
the expression of RDE-1, a C. elegans argonaut protein which is required
for RNA interference. This resulted in active RNAi at 15 °C but not at
25 °C. Furthermore, they observed that the switching ON and OFF is
much faster than transferring animals from RNAi-mediating bacteria
to non-RNAi inducing bacteria and vice-versa [56].
The dilution of bacteria containing a speciﬁc RNAi construct with
non-RNAi mediating bacteria may decrease the efﬁciency of knocking
down a certain gene. In that case of mild RNA interference, lethality
effects and other very strong phenotypes are reduced and it might still
be possible to study the function of these special genes.
The target of RNAi is known. This is onemajor difference to EMSmu-
tagenesis that cannot be directed to speciﬁc genes. Therefore, besides
genome-wide RNAi screens, one can also screen in a smaller subset ofcandidate genes for example based on previous microarray data,
GWAS data, interactome studies, etc. Colaiácovo and colleagues per-
formed for example a RNAi screen to check for germline phenotypes
in a subset of genes that were generated by a previous microarray
analysis of Reinke et al. that was focusing on germline-enriched gene
expression [57,58]. In another screen we were looking for genes that,
when knocked down, increased the number of alpha-synuclein inclu-
sions in a Parkinson's disease C. elegans model [59]. This group of 80
genes was then further used for a second RNAi screen in order to ﬁnd
candidates that, when knocked down, induced motility changes in the
disease background [60].
RNAi efﬁciency of bacterial clones in the library can differ. Whereas
some dsRNAs induce gene silencing closely to a knockout of a gene,
others only generate a mild knockdown. One should always be aware
that RNAi is only silencing gene activity and that it is not a full knockout
of a gene. It is estimated that about 10–30% of candidates are scored as
false negatives as the RNAi is not efﬁcient enough to result in an obvious
phenotype. On the other hand the percentage of false positives is
relatively low (0.4%) [61]. It is also important to keep in mind that
RNA interference is acting at the mRNA level and therefore only
inﬂuencing the expression of a protein. That means that the stability
of a protein is highly inﬂuencing the RNAi effect as already generated
proteins and their activity are not affected anymore.
Results can also differ from one experiment to the other using the
same bacteria clone to silence a speciﬁc gene. For example the freshness
of thematerial can be crucial (IPTG, Ampicillin, RNAi construct contain-
ing bacteria) [51]. In contrast, a knockout mutant e.g. by EMSmutagen-
esis has the advantage that it results in a stable genotype. Results of the
RNAi screen should therefore be conﬁrmed by single experiments with
the candidate genes, preferentially with a gene mutant strain.
A clear phenotype for scoring ismandatory for any successful screen.
An obvious easy-to-recognize phenotype as well as automation of
scoring facilitates the screening process.
The small size of the animals, the variety of simple phenotypes that
are often results of one single gene disruption or silencing, the her-
maphroditic reproduction, the homology to higher organisms (see
above) and the knowledge of the C. elegans genome, cell-distribution
and nematode anatomy make this animal an optimal model organism
to identify the function of genes via any kind of high-throughput screen.
3. From genome to function: what have genetic screens taught us?
One of the advantages of C. elegans is that it is amenable to generate
“humanized”models of human diseases. For the purpose of this review,
we will describe as an example C. elegansmodels of neurodegenerative
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be successfully recapitulated in the nematode, such as protein aggre-
gation [62]. Indeed, one of the common features in neurodegenera-
tive diseases is the presence of protein aggregates in the brains of
affected patients. These structures originate from protein misfolding
and aggregation of so-called “aggregation-prone proteins”. To name
a few, these can be the amyloid-beta in Alzheimer's disease (AD),
mutant huntingtin in Huntington's disease (HD) and alpha-synuclein
in Parkinson's disease (PD) [63]. By mechanisms that are still to be
unraveled, these aggregation-prone proteins adopt a distinct conforma-
tion,which is thought be a toxic gain-of-function [64,65]. The general un-
derstanding is that aggregation (or inclusion formation) renders cellular
protection by sequestering misfolded proteins, therefore preventing po-
tentially toxic protein–protein interactions [65,66].
Several nematode models have been generated to recapitulate mo-
lecular aspects of diseases, including HD, PD, AD and muscular dystro-
phy [59,67–72]. Although they do not feature clinical aspects of the
disease, they provide the means to understand the molecular mecha-
nisms in these diseases. Genetic screens performed in some of these
models represent quick, unbiased methods that have enabled insights
into the underlying mechanisms of neurodegeneration. Indeed, many
of the diseasemodiﬁers discovered in C. eleganswere found to be repro-
ducible in human cell-based models and other animal models such as
mice, strengthening the validity of using this small organism to study
complex human diseases, as summarized in Table 2 [69,73–78].
3.1. C. elegans models for polyglutamine diseases
Polyglutamine diseases comprise a subset of neurodegenerative dis-
orders that include HD, spinocerebellar ataxias (−1, −2, −6, −7,
−17), Machado–Joseph disease (also know as spinocerebellar ataxia
3) and spinobulbar muscular atrophy [79]. The common characteristic
of polyglutamine diseases is an abnormal expansion of CAG triplets
(which encode glutamine) in the coding region of the disease gene.
Although the length of the CAG repeatmay vary from individual to indi-
vidual, the threshold to develop disease is around 40 CAG repeats (ex-
cept for SCA6), which cause a polyglutamine expansion in the protein
that is prone to aggregate. The larger the CAG repeat the earlier onset
will occur and the more severe the disease phenotype will be. A more
detailed and complete information on polyglutamine diseases is
reviewed elsewhere [79].
In C. elegans, several differentmodels have successfully recapitulated
protein aggregation. Similarly to what occurs in humans, the length of
the CAG repeats also determines the aggregation phenotype inC. elegans.
At least three models have been generated to induce polyglutamine-
associated toxicity in neurons by expressing expanded polyglutamine
stretches in ASH sensory neurons, touch receptor neurons or the entire
nervous system of C. elegans [68,80–82]. Polyglutamine aggregation
has been modeled in the body wall muscle cells of C. elegans [68]. In
this model, expanded polyglutamine stretches are fused to a yellow
ﬂuorescent protein (YFP) under the unc-54 promotor, which is speciﬁc
to the body wall muscle. The aggregation and toxicity phenotype is
polyglutamine length-dependent. As the animal ages, the accumulation
of protein aggregates increases, which is associated with toxicity [68].
This model has been widely used for genetic screens to discover
enhancers and/or suppressors of polyglutamine proteotoxicity. Two
genome-wide RNAi screens revealed modiﬁer genes and classiﬁed
them according to their biological function [83,84]. In the ﬁrst screen,
Q35 animals were fed with dsRNA-producing bacteria and scored for
genes that, when downregulated, provoked premature polyglutamine
aggregation [83]. The major functional classes included RNA synthesis
and processing, protein synthesis, folding, transport and degradation
and components of the proteasome. In the second screen, the authors
sought for genes that drive aggregation in Q35 animal and therefore
the selection was made for genes that suppressed polyglutamine-
induced aggregation when downregulated [84]. With this study, anew subset of modiﬁer genes was recently found to belong to broader
biological functions, namely cell cycle, cell structure, protein transport
and energy andmetabolism [83,84]. Therefore, proteotoxicity is not de-
rived only from protein-related processes but rather a more diverse
spectrum of biological functions that also have an effect on protein
misfolding and aggregation. Interestingly, nine of these recently identi-
ﬁed modiﬁer genes were able to fold misfolded proteins back into the
native state when constitutively expressed in misfolding mutants [84].
Forward genetics have also been used to identify modiﬁers of
proteotoxicity. One such screen consisted in treating Q40-expressing
wormswith EMS. The aimwas to ﬁnd positive regulators of aggregation
by selecting genes that suppressed protein aggregationwhen chemical-
ly mutated by EMS. The screen revealed MOAG-4 (modiﬁer of aggrega-
tion) as a general aggregation-promoting factor in polyglutamine,
Parkinson's and Alzheimer's disease models [76]. Inactivating MOAG-4
alleviated from polyglutamine-induced aggregation and toxicity; more-
over, this effect was functionally conserved in the human orthologs
SERF1A and SERF2. A recent follow-up on one of these orthologs
showed that SERF1A is a speciﬁc aggregation promoting factor, since it
was able to bind speciﬁcally to amyloidogenic proteins, including
alpha-synuclein, prion protein, amyloid-beta and huntingtin, but not
to non-amyloidogenic proteins [85].
Genetic screens have also been used to ﬁnd regulators of proteo-
toxicity using theC. elegansneuronal system. An RNAi screen performed
in a C. elegansmodel expressing 128 polyQ stretches in the touch recep-
tor neurons resulted in 662 genes that either enhanced or suppressed
neuron toxicity, asmeasured by loss of touch response [77]. Comparison
of these disease modiﬁer genes to gene expression data in two mouse
models of HD showed that there was an overlap of 49 genes that were
dysregulated in the striatum of either model, emphasizing the power
of using C. elegans to ﬁnd novel regulators of proteotoxicity relevant in
human diseases.
3.2. C. elegans models for Parkinson's disease
Parkinson's disease (PD) is the secondmost commonneurodegener-
ative disease (after Alzheimer's disease) that affects 1% of the popula-
tion over the age of 50. Clinically, it is characterized by resting
tremors, rigidity, bradykinesia and postural instability [86,87]. The de-
fects in themotor system result from the progressive loss of dopaminer-
gic neurons in the substantia nigra pars compacta (SNpc), which project
and innervate the neurons in the caudate and putamen. Consequently,
there is a reduction of dopamine levels, which is the neurotransmitter
that plays a role in the coordination of body movements. Besides
motor disabilities, PD patients can experience non-motor symptoms
such as autonomic dysfunction, sleep disturbances and neuropsychiat-
ric symptoms [88]. Most cases of PD are sporadic (about 95%) with un-
known etiology. It has been suggested that disease can result from the
accumulation of toxins (pesticides and heavy metals) over the years.
Only 5% of PD has a familial origin and is associated with genetic muta-
tions [88]. However, there are neuropathological hallmarks common to
both sporadic and familial forms of PD. These are the loss of dopaminer-
gic neurons in the SNpc, that result from the degeneration of the
nigrostriatal pathway which leads to the motor symptoms described
earlier as well as the formation of intraneuronal protein aggregates
known as Lewy bodies and Lewy neurites in the surviving neurons,
which contain alpha-synuclein.
Alpha-synuclein is a small (140 amino acids) natively soluble, mo-
nomeric protein that is predominantly expressed in the brain and is
enriched in presynaptic terminals [89]. Although the precise function
of this protein remains unclear, it is thought to be involved in the regu-
lation of dopamine neurotransmission, vesicular trafﬁcking and mod-
ulation of synaptic function and plasticity [90–92]. Three different
mutations in the alpha-synuclein gene (A53T, A30P and E46K) cause
autosomal-dominant PD [93–95] and genomic duplications and tripli-
cations of the gene have also been identiﬁed; suggesting that
Table 2
Summary of genetic screens performed in C. elegansmodels of neurodegenerative diseases.
Model Transgene Tissue Genetic screen Modiﬁer hits Mammalian
ortholog
Cellular process(es) Transposed
to
Reference
PolyQ diseases Q35-YFP Body wall muscle Genome-wide
RNAi screen
186 genes n.a. RNA synthesis and processing, protein
synthesis, folding,
transport, degradation, components of
the proteasome
n.a. [83]
PolyQ diseases Q35-YFP Body wall muscle Genome-wide
RNAi screen
88 genes n.a. Cell cycle, cell structure, protein
transport and energy and metabolism
n.a. [84]
PolyQ diseases Q40-YFP Body wall muscle EMS screen MOAG-4 SERF1A
and SERF2
Unknown Human cell
models
[76]
PD Alpha-synuclein-YFP Body wall muscle Genome-wide
RNAi screen
80 genes n.a. Vesicle trafﬁcking, lipid metabolism,
lifespan
n.a. [59]
PD Alpha-synuclein-YFP Body wall muscle RNAi 30 genes,
including TDO-2
TDO Tryptophan metabolism n.a. [60]
PD Alpha-synuclein-GFP Body wall muscle
and DA neurons
Hypothesis-based
RNAi screen
20 genes,
including ATGR7
ATG7 Autophagy Mice [69,78]
PD Alpha-synuclein
(WT, A53T, A30P)
Whole nervous
system
RNAi screen 10 genes,
including
APA-2; APS-2
n.a. Vesicular trafﬁcking n.a. [70]
AD Tau Whole nervous
system
Genome-wide
RNAi screen
60 genes 38 have
human
homologs
Kinases and phosphatases; protein
folding, stress response and
degradation; transcription; proteolysis;
neurotransmission and signaling;
neuronal regeneration
n.a. [75]
1956 O. Sin et al. / Biochimica et Biophysica Acta 1842 (2014) 1951–1959overproduction of wild type alpha-synuclein is sufﬁcient to cause dis-
ease [96,97].
Genetic screens performedwith thismodel have been supporting an
important relationship between alpha-synuclein and vesicle transport.
The “humanized” model of C. elegans for PD expresses the human
alpha-synuclein fused to YFP in the body wall muscle. Phenotypically,
immobile YFP-positive foci can be seen in the muscle cells and these
foci increase in number and correlate with age-dependent toxicity. An
unbiased genome-wide RNAi screen with this model showed 80 modi-
ﬁer genes that, when suppressed, provoked premature alpha-synuclein
inclusion formation [59]. A follow-up on those modiﬁer genes revealed
tdo-2, a gene involved in tryptophan degradation, as a general regulator
of protein homeostasis during aging [60]. Moreover, 49 of the original
80 modiﬁer genes had human homologs, which were enriched for
genes related to vesicular trafﬁcking functions. In another screen using
a similar model, nematode genes orthologous to human familial PD
genes were preselected to perform a hypothesis-based RNAi screen
[69]. A subset of candidate genes from the initial screenwas then further
analyzed in another C. elegansmodel, expressing alpha-synuclein in the
dopamine neurons, in order to assess their relevance at the neuronal
level. This study revealed ﬁve candidate genes that were able to protect
from alpha-synuclein-induced dopaminergic neurodegeneration.
Again, the most representative class of genes here was associated with
vesicular trafﬁcking, with the exception of the autophagy-related gene
Atgr7, of which the mammalian ortholog (Atg7) was previously impli-
cated in neurodegeneration inmice [78]. Also, a serine/threonine kinase
involved in axonal elongation, UNC-51, was found to be homologous to
the previously associated risk factor ULK-2, as revealed by a genome-
wide association study performed in PD patients [98]. Parallel to these
ﬁndings, Kuwahara et al. were able to pinpoint two genes, apa-2 and
aps-2, that when knockdown by RNAi increase alpha-synuclein-
induced neurotoxicity in a C. elegans model expressing the transgene
in the whole nervous system [70]. These two genes encode for subunits
of the AP-2 adaptor complex, which mediates the internalization of
cargo into the cell from the extracellular space via clathrin-mediated en-
docytosis [99].
3.3. C. elegans models for Alzheimer's disease
Alzheimer's disease (AD) is the most prevalent neurodegenerative
disease, which is predicted to affect 66 million people worldwide by
2030 [100]. It represents the most common form of dementia, leadingto clinical symptoms such as memory loss and mood swings. Aging
and lifestyle are risk factors for development of AD, but 70% of the
cases are attributable to genetics [101]. Themain neuropathological fea-
tures are thepresence of extracellular amyloid-beta plaques,which con-
sist of an accumulation of aggregated amyloid-beta, and intraneuronal
tangles of hyperphosphorylated tau. Mutations in several genes can
lead to the development of AD, including mutations in genes encoding
for the amyloid-precursor protein (APP), presenelin 1 (PSEN1) and
presenelin 2 (PSEN2). These genes are part of the APP cleavage pathway
and mutations in these genes promote the processing of APP towards
the amyloidogenic pathway, promoting the formation of amyloid-
beta. Amyloid-beta peptides can have different lengths, including 40
or 42 amino acids. Amyloid-beta 42 is the most common species
found in the amyloid plaques, indicating its propensity to rapidly aggre-
gate in comparison to amyloid-beta 40.
Tau is encoded by the microtubule-associated tau protein (MAPT)
gene and predominantly expressed in the nervous system. As to its
function, it is known to associate and stabilize microtubules. It has
been already classiﬁed as one of the risk genes for developing AD by
at least two independent studies [102,103].
There are several models in C. elegans that express either human
amyloid-beta or tau. In the ﬁrst case, the worms express amyloid-beta
3–42 in the body wall muscles which causes the progressive accumula-
tion of amyloid-beta 3–42 in the muscle cells and paralysis, which
worsens with aging [71,104]. There have been several variations to
this model, either combined with inducible systems, driving expression
in neurons or, more recently, expressing full-length amyloid-beta 1–42
[105–107]. On the other hand, tau-expressingmodels have been specif-
ic to neuronal cells and the phenotype is either worsening of uncoordi-
natedmovement or insensitivity to the touch response due to transgene
expression [75,108,109].
Genetic screens in C. elegansmodels for AD have been scarce. So far,
there has been no genetic screen performed in any of the models ex-
pressing amyloid-beta. There is only one report on genome-wide
RNAi done in a tau-expressing model [75]. Sixty modiﬁer genes were
discovered to belong to several functional classes including, kinases,
chaperones, proteases and phosphatases. Of these, 38 had homologs
in humans but, more importantly, 6 had already been associated with
disease, either in humans or other animal models. One of these modi-
ﬁers was the nicotinic acetylcholine receptor alpha-7 (nAchR), a
ligand-gated ion channel expressed in the human brain and known to
contribute to tau phosphorylation [110].
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Genetic screens are powerful means to ﬁnd genes involved in a
certain biological process of interest and their function. The fact that
C. elegans is a tractable system to model human diseases further allows
one to perform genome-wide screenings in a relatively quick and unbi-
ased manner. Genetic screens can have two outcomes, both being
equally informative. On the one hand, new genes are discovered and
therefore novel pathways are implicated, giving fresh perspectives on
the biological process being studied. On the other hand, genetic screens
that reveal genes already known to be associatedwith disease strength-
en the importance of those genes in pathogenesis. Many screens that
start with a genome-wide approach end up with an extensive list of
candidate genes that are classiﬁed according to their functional class.
From here, a selection of these genes should be reﬁned and prioritized
in order to study further their individual contribution to pathogenesis.
One of the critical points is considering those that might have signiﬁ-
cance at the mammalian level. Additionally, if the human gene can
replace the function of the endogenous one, it demonstrates evolution-
ary conservation of function and enables one to extrapolate ﬁndings
from small organisms to complex humandiseases. It is, therefore, essen-
tial to validate the genes from the screen in higher organisms. However,
it is also often that a screenmight reveal genes that do not have a direct
sequence homolog inmammals. Nevertheless, theymay be indicators of
other genes that may be functional orthologs or otherwise regulators of
genes with a role in human disease (e.g. transcription factors).
Another contribution of genetic screensmay be to provide novel tar-
gets for drug development [111]. Although not all features of a complex
human disease are fully recapitulated in the nematode, one can argue
that its simplicity can be advantageous. Especially, because analysis of
the expression of the causative gene and its interactors or modiﬁers
can be done without other confounding factors inherent to the com-
plexity of the human biology.
Genome-wide association studies (GWAS) have gained importance
in the last ten years, becoming one of the forefront strategies to ﬁnd
common genetic factors associated with susceptibility to develop dis-
ease. One challenge now is to establish the functional consequences of
these genetic variations. Coupling genetic screens or candidate gene ap-
proach in C. elegans to ﬁnd causative genes may represent a quick and
inexpensive way to assess functional relevance of associated variations
and consequently obtain concrete targets to act upon. For instance, a
genome-wide toxicity screen in yeast revealed 6 modiﬁers of amyloid-
beta toxicity that were previously identiﬁed as risk factors in GWAS
[112]. Importantly, those modiﬁers were functionally conserved from
yeast, to C. elegans and to rat. Another study by Shulman et al. showed,
for the ﬁrst time, a link between an AD risk factor and a causative gene
by functional screening in the ﬂy [113].
Although this review focused in C. elegans models for neurode-
generative diseases, it should be noted that C. elegans is a model or-
ganism for other human diseases as well. C. elegans has been used
to model certain aspects of cancer, diabetes, obesity, polycystic kid-
ney disease, muscular dystrophy and innate immunity, to name a
few. A more complete view of these different disease models is sum-
marized elsewhere [111].
All in all, genetic screens in small organisms such as C. elegans can
not only aid to dissect fundamental biological questions but also have
the versatility of being adapted to model complex human diseases,
such as neurodegenerative diseases. Moreover, its attributes make it a
tractable system to drug target discovery and compound screening, em-
phasizing the potential of this organism to extrapolate ﬁndings from
small organisms to higher vertebrates.
Online links
– Textpresso, a full text literature searches of C. elegans (http://www.
textpresso.org/)– Worm Interactome Database (http://interactome.dfci.harvard.edu/
C_elegans/index.php)
– The Caenorhabditis Genetic Center, with an extensive list of strains
(http://www.cbs.umn.edu/CGC/)
– Wormbase, a complete database of genetics, genomics and biology
of C. elegans (www.wormbase.org)
– Wormbook, a comprehensive, open-access collection of original,
peer-reviewed chapters covering topics related to the biology of
C. elegans and other nematodes (http://wormbook.org)
– C. elegans Gene Knockout Consortium, which creates knockout
strains (http://celeganskoconsortium.omrf.org/)
– National Bioresource Project, which generates, collects, stores and
distributes deletion mutants of C. elegans (http://www.shigen.nig.
ac.jp/c.elegans/index.jsp)
– Wormatlas, a database of behavioral and structural anatomy of
C. elegans (http://www.wormatlas.org)
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